Rotigotine Transdermal Formulation with HPC Crystallization Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing transdermal patches containing rotigotine suffer from crystal precipitation due to low solubility in silicone adhesives, leading to stability issues and reduced shelf-life.
Innovation Solution
A transdermal absorption formulation using hydroxypropyl cellulose (HPC) as a crystallization inhibitor, combined with a silicone-based polymer adhesive, to maintain rotigotine in a dissolved state, along with a fatty acid as a solubilizer and optional antioxidants, ensuring stability and adhesion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If silicone-based polymer adhesive is used to improve transdermal permeability of rotigotine, then transdermal delivery is improved, but crystal precipitation occurs due to low solubility
Solution Approach 1:
The patent introduces polyvinyl pyrrolidone (PVP) as an intermediary substance that mediates between rotigotine and silicone adhesive. PVP acts as a solubilizing agent that forms a complex with rotigotine, enabling it to dissolve in the silicone-based adhesive system without crystallizing, thus maintaining both transdermal delivery efficiency and formulation stability
Solution Approach 2:
The patent creates a composite adhesive system combining silicone-based polymer adhesive with polyvinyl pyrrolidone and rotigotine. This composite formulation leverages the adhesive properties of silicone while using PVP to prevent rotigotine crystallization, achieving a synergistic effect that maintains both transdermal permeability and storage stability
2Stability of the object's composition
If polyvinyl pyrrolidone polymers are added to minimize rotigotine precipitation, then crystallization is reduced, but partial crystallization still occurs on commercial products
Solution Approach 1:
The patent optimizes the concentration ratio of PVP to rotigotine in the formulation. By carefully controlling this parameter, the patent achieves complete prevention of crystallization throughout the shelf-life period, exceeding the performance of prior art formulations that allowed partial crystallization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation prevents rotigotine crystallization, maintains stability, and enhances transdermal delivery, while ensuring adhesion without physical separation of layers, comparable to commercial products.
Implementation Method 1
hydroxypropyl cellulose (HPC) as a crystallization inhibitor
Implementation Method 2
silicone adhesives are used to improve the transdermal permeability of the rotigotine
Implementation Method 3
a self-adhesive matrix layer
Data Source
Figure 1
Figure 2~3
AI summary
In a formulation for transdermal absorption and a method for preparing same according to the present invention, the formulation for transdermal absorption comprises: rotigotine or a pharmaceutically acceptable salt thereof as an active ingredient; hydroxypropyl cellulose (HPC) as a crystallization prevention agent; and a drug-containing adhesive layer comprising a silicone-based polymer adhesive.